• 1
    Asherson RA. A primary antiphospholipid syndrome? J Rheumatol 1988;15:17426.
  • 2
    Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine 1989;68:35374.
  • 3
    Briley DP, Coull BM, Goodnight SH Jr. Neurological disease associated with antiphospholipid antibodies. Ann Neurol 1989;25:2217.
  • 4
    Provenzale JM, Heinz ER, Ortel TL, et al. Antiphospholipid antibodies in patients without systemic lupus erythematosus: neuroradiologic findings. Radiology 1994;192:5317.
  • 5
    Levine SR, Welch KMA. The spectrum of neurological disease associated with antiphospholipid antibodies: lupus anticoagulants and anticardiolipin antibodies. Arch Neurol 1987;44:87683.
  • 6
    Firer M, Sirota P, Schild K, et al. Anticardiolipin antibodies are elevated in drug-free multiply affected families with schizophrenia. J Clin Immunol 1994;14:738.
  • 7
    Perju-Dumbrava L, Zeiler K, Kapiotis S, et al. Anticardiolipin antibodies in stroke and in other neurological disorders. Rom J Neurol Psychiatry 1995;33:13743.
  • 8
    Asherson RA, Khamashta MA, Gil A, et al. Cerebrovascular disease and antiphospholipid antibodies in SLE, lupus-like disease and the primary antiphospholipid syndrome. Am J Med 1989;86:3919.
  • 9
    Asherson RA, Lubbe WF. Cerebral and valve lesions in systemic lupus erythematosus: association with antiphospholipid antibodies? J Rheumatol 1988;15:53943.
  • 10
    Schmidt R, Auer-Grumbach P, Fazekas F, et al. Anticardiolipin antibodies in normal subjects: neuropsychological correlates and MRI findings. Stroke 1995;26:74954.
  • 11
    Gorman DG, Cummings JL. Neurobehavioral presentations of the antiphospholipid syndrome. J Neuropsychol Clin Neurosci 1993;5:3742.
  • 12
    Harris EN, Gharavi AE, Asherson RA, et al. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol 1984;2:4751.
  • 13
    Anderson D, Bell D, Lodge R, et al. Recurrent cerebral ischemia and mitral valve vegetation in a patient with antiphospholipid antibodies. J Rheumatol 1987;14:83941.
  • 14
    Levine SR, Welch KMA. Cerebrovascular ischemia associated with lupus anticoagulant. Stroke 1987;18:25763.
  • 15
    Angelini R, Ravelli A, Caporali R, et al. High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia. Pediatrics 1994;94:5003.
  • 16
    Scott TF, Hess D, Brillman J. Antiphospholipid antibody syndrome mimicking multiple sclerosis clinically and by magnetic resonance imaging. Arch Intern Med 1994;154:91720.
  • 17
    Fields RA, Sibbitt WL, Toubbeh H, et al. Neuropsychiatric lupus erythematosus, cerebral infarction, and anticardiolipin antibodies. Ann Rheum Dis 1990;49:1147.
  • 18
    Herranz MT, Rivier G, Khamashta MA, et al. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:56971.
  • 19
    Toubi E, Khamashta MA, Panarra A, et al. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995;99:397401.
  • 20
    Verrot D, San-Marco M, Dravet C, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997;103:337.
  • 21
    Inzelberg R, Korczyn AD. Lupus anticoagulant and late onset seizures. Acta Neurol Scand 1989;79:1148.
  • 22
    Spreafico R, Binelli S, Bruzzone MG, et al. Primary antiphospholipid syndrome (PAPS) and isolated partial seizures in adolescence: a case report. Ital J Neurol Sci 1994;15:297301.
  • 23
    Angelini L, Granata T, Zibordi F, et al. Partial seizures associated with antiphospholipid antibodies in childhood. Neuropediatrics 1998;29:24953.
  • 24
    McNeil HP, Simpson RJ, Chesterman CN, et al. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:41204.
  • 25
    Galli N, Cornfurius P, Maassen C, et al. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:15447.
  • 26
    Del Papa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid antibodies: human polyclonal and monoclonal anti-β2 glycoprotein I antibodies react in vitro with endothelial cells through adherent β2 glycoprotein I and induce endothelial activation. Arthritis Rheum 1997;40:55161.
  • 27
    Meroni PL, Raschi E, Camera M, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000;15:23740.
  • 28
    Caronti B, Pittoni V, Palladini G, et al.. Anti-β2 glycoprotein I antibodies bind to central nervous system. J Neurol Sci 1998;156:2119.
  • 29
    Chapman J, Cohen-Armon M, Shoenfeld Y, et al. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999;8:12733.
  • 30
    Galli M, Barbui T. Anti-prothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999;93:214957.
  • 31
    Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome? J Autoimmun 2000;15:1015.
  • 32
    De Groot PG, Harbach DA, Simmelink MJ, Van Oort E, Derksen RH. Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant. Lupus 1998;7:S326.
  • 33
    Shtark MB, Gainutdinov KL, Khichenko VI, et al. Biological effects of antibrain antibodies. Ann NY Acad Sci 1987;496:40515.
  • 34
    Karpiak SE, Graf L, Rapport MM. Antiserum to brain gangliosides produces recurrent epileptiform activity. Science 1976;194:7357.
  • 35
    Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:38999.
  • 36
    Di Simone N, Meroni PL, Del Papa N, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered β2 glycoprotein I. Arthritis Rheum 2000;43:14050.
  • 37
    Avc̆in T, Ambrozic A, Kuhar M, et al. Anticardiolipin and anti-β2 glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology 2001;40:56573.
  • 38
    Horbach DA, Van Oort E, Derksen RHWM, et al. The contribution of anti-prothrombin antibodies to lupus anticoagulant activity. Thromb Haemost. 1998;79:7905.
  • 39
    Bayer PM, Bauerfeind S, Bienvenu J, et al. Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay. J Autoimmun 1999;13:8993.
  • 40
    Tan EM, Feltkamp TEW, Smolen JS, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 1997;40:160111.
  • 41
    Cimaz R, Stramba-Badiale M, Brucato A, et al. QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block. Arthritis Rheum 2000;43:104953.
  • 42
    Harris EN. The Second International Anti-cardiolipin Standardization Workshop/The Kingston Anti-phospholipid Antibody Atudy (KAPS) group. Am J Clin Pathol 1990;94:47684.
  • 43
    Aarli JA. Immunological aspects of epilepsy. Brain Dev 1993;15:4150.
  • 44
    Bartolomei F, Boucraut J, Barriè M, et al. Cryptogenic partial epilepsies with anti-GM1 antibodies: a new form of immune-mediated epilepsy? Epilepsia 1996;37:9226.
  • 45
    Takigawa T, Yasuda H, Kikkawa R, et al. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol 1995;37:43642.
  • 46
    Sadiq SA, Thomas FP, Kilidireas K, et al. The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology 1990;40:106772.
  • 47
    Koike T, Matsuura E. Anti-β2 glycoprotein I antibody: specificity and clinical significance. Lupus 1996;5:37880.
  • 48
    Martinuzzo ME, Forastiero RR, Carreras LO. Anti-β2 glycoprotein I antibody: detection and association with thrombosis. Br J Hematol 1995;89:397402.
  • 49
    Cabiedes J, Cabral AL, Alarcon-Segovia D. Clinical manifestation of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2 glycoprotein I than with antiphospholipid antibodies. J Rheumatol 1995;22:1899906.
  • 50
    Amengual O, Atsumi T, Khamashta MA, et al. Specificity of ELISA for antibody to β2 glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:123943.
  • 51
    McNally T, Mackie IJ, Isenberg DA. Increased levels of β2 glycoprotein I antigen and β2 glycoprotein I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 1995;34:10316.
  • 52
    Viard JP, Amoura Z, Bach JF. Association of anti-β2 glycoprotein I antibodies with lupus type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992;93:1816.
  • 53
    Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autoimmun 2000;15:16372.DOI: 10.1006/jaut.2000.0401
  • 54
    Alarcon-Segovia D, Cabral AR. The antiphospholipid/cofactor syndromes. J Rheumatol 1996;23:131922.
  • 55
    Roubey RAS, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to β2 glycoprotein I and conventional anticardiolipin immunoassay. Arthritis Rheum 1996;39:16067.
  • 56
    Forastiero RR, Martinuzzo ME, Kordich LC, et al. Reactivity to β2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 1996;75:71720.
  • 57
    Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to β2 glycoprotein and clinical manifestation in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:146674.
  • 58
    Balestrieri G, Tincani A, Spatola L, et al. Anti-β2 glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus 1995;4:12230.
  • 59
    De Groot PG, Horbach DA, Simmelink MJA, et al. Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant. Lupus 1998;7(suppl 2):326.
  • 60
    Asherson RA, Derksen RHWM, Bouma BNM, et al. Chorea in systemic lupus erythematosus and “lupus-like” disease: association with antiphospholipid antibodies. Semin Arthritis Rheum 1987;16:2539.
  • 61
    Tietjen GE. Migraine and antiphospholipid antibodies. Cephalalgia 1992;12:6974.DOI: 10.1046/j.1468-2982.1992.1202069.x
  • 62
    Lavalle C, Pizarro S, Drenkard C, et al. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 1990;17:347.
  • 63
    Harris EN, Englert H, Derue G, et al. Antiphospholipid antibodies in acute Guillain-Barrè syndrome. Lancet 1983;ii:13612.
  • 64
    Angelini L, Zibordi F, Zorzi G, et al. Neurological disorders, others than stroke, associated with antiphospholipid antibodies in childhood. Neuropediatrics 1986;27:14953.
  • 65
    Galli M, Finazzi G, Bevers EM, et al. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin and β2 glycoprotein I-dependent antiphospholipid antibodies. Blood 1995;86:61722.
  • 66
    De Ponti F, Lechini S, Cosento M, et al. Immunological adverse effects of anticonvulsants: what is their clinical relevance? Drug Saf 1993;8:23550.